N. Azarnia
About
N. Azarnia is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, N. Azarnia has authored 52 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 20 papers in Oncology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in N. Azarnia's work include Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (13 papers) and Lung Cancer Treatments and Mutations (13 papers). N. Azarnia is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (13 papers) and Lung Cancer Treatments and Mutations (13 papers). N. Azarnia collaborates with scholars based in United States, France and Spain. N. Azarnia's co-authors include Dong M. Shin, Merrill S. Kies, Eric K. Rowinsky, José Baselga, J. Giralt, Paul M. Harari, James A. Bonner, David Raben, Christopher U. Jones and Jacek Jassem and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
N. Azarnia
52 papers receiving 6.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N. Azarnia United States | 24 | 3.5k | 2.7k | 2.0k | 1.4k | 1.3k | 52 | 6.5k | ||
| A. Dimitrios Colevas United States | 51 | 3.4k 1.0× | 2.1k 0.8× | 2.6k 1.3× | 1.6k 1.2× | 2.2k 1.7× | 197 | 7.6k | ||
| Didier Cupissol France | 36 | 4.9k 1.4× | 4.4k 1.6× | 3.0k 1.5× | 1.6k 1.2× | 2.5k 1.9× | 160 | 8.9k | ||
| Jan B. Vermorken Belgium | 23 | 3.1k 0.9× | 2.1k 0.8× | 2.2k 1.1× | 1.3k 1.0× | 1.4k 1.0× | 45 | 5.6k | ||
| Jan B. Vermorken Belgium | 35 | 2.2k 0.6× | 1.6k 0.6× | 2.1k 1.0× | 731 0.5× | 2.3k 1.7× | 96 | 5.6k | ||
| Frédéric Peyrade France | 29 | 3.3k 0.9× | 2.5k 0.9× | 2.2k 1.1× | 897 0.7× | 1.5k 1.1× | 138 | 5.7k | ||
| F. Cognetti Italy | 27 | 2.3k 0.7× | 1.3k 0.5× | 2.2k 1.1× | 933 0.7× | 1.9k 1.5× | 129 | 4.8k | ||
| Julie A. Kish United States | 33 | 3.1k 0.9× | 2.5k 0.9× | 5.2k 2.6× | 846 0.6× | 3.7k 2.8× | 82 | 7.3k | ||
| Ricardo Hitt Spain | 28 | 4.0k 1.2× | 2.9k 1.1× | 3.5k 1.7× | 1.5k 1.1× | 2.0k 1.5× | 69 | 6.7k | ||
| Federica Perrone Italy | 50 | 3.6k 1.0× | 2.7k 1.0× | 1.0k 0.5× | 2.1k 1.6× | 2.0k 1.5× | 235 | 7.9k | ||
| Muhyi Al‐Sarraf United States | 47 | 4.4k 1.3× | 6.0k 2.2× | 5.0k 2.5× | 1.1k 0.8× | 7.1k 5.4× | 146 | 12.2k |
Countries citing papers authored by N. Azarnia
Since
Specialization
Citations
This map shows the geographic impact of N. Azarnia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Azarnia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Azarnia more than expected).
Fields of papers citing papers by N. Azarnia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by N. Azarnia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Azarnia. The network helps show where N. Azarnia may publish in the future.
Co-authorship network of co-authors of N. Azarnia
This figure shows the co-authorship network connecting the top 25 collaborators of N. Azarnia. A scholar is included among the top collaborators of N. Azarnia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Azarnia. N. Azarnia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Garcia‐Manero, Guillermo, Shyamala Navada, Pierre Fenaux, et al.. (2019). Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS). Blood. 134(Supplement_1). 4268–4268.
2.
Fenaux, Pierre, Aref Al‐Kali, Maria R. Baer, et al.. (2015). Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.. Journal of Clinical Oncology. 33(15_suppl). e18079–e18079.
3.
Silverman, Lewis R., Pierre Fenaux, Peter L. Greenberg, et al.. (2015). Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome.. Journal of Clinical Oncology. 33(15_suppl). 7017–7017.
4.
Baselga, José, Alexey Manikhas, Javier Cortés, et al.. (2014). Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of Oncology. 25(3). 592–598.
5.
Peña, Lorena de la, Javier Cortés, Alexey Manikhas, et al.. (2013). Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology. 31(15_suppl). 517–517.
6.
Bonner, James A., Paul M. Harari, J. Giralt, et al.. (2006). Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine. 354(6). 567–578.
7.
Batist, Gerald, et al.. (2006). Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs. 17(5). 587–595.
8.
Bonner, James A., Paul M. Harari, J. Giralt, et al.. (2006). EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. Journal of Clinical Oncology. 24(18_suppl). 5510–5510.
9.
Chan, Stephen, N. Davidson, Elona Juozaitytė, et al.. (2004). Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of Oncology. 15(10). 1527–1534.
10.
Harris, Lyndsay N., Gerald Batist, Robert J. Belt, et al.. (2001). Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma. Cancer. 94(1). 25–36.
11.
Chan, Stephen L., et al.. (2001). Lipsome-encapsulated doxorubicin (MYOCET) and cyclophosphamide is superior to epirubicin and cyclophosphamide in first-line therapy of metastatic breast cancer. European Journal of Cancer. 37. 28–28.
12.
Cheung, Tony, S. C. Remick, N. Azarnia, et al.. (1999). AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.. PubMed. 5(11). 3432–7.
13.
Cheung, Tony, et al.. (1998). PHASE II STUDY OF LIPOSOMAL DOXORUBICIN (TLC D-99) IN THE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA (KS).. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 17(4). A16–A16.
14.
Cody, Robert L., David Stewart, Malcolm Moore, et al.. (1993). Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Breast Cancer. American Journal of Clinical Oncology. 16(6). 526–528.
15.
Larson, Richard A., Roger Day, N. Azarnia, et al.. (1992). The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study. British Journal of Haematology. 82(2). 337–346.
16.
Curran, Walter J., Robert E. Krisch, James D. Cox, et al.. (1991). Comparison of the radiation therapy oncology group and american joint committee on cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the radiation therapy oncology group protocol 83-11. Cancer. 68(3). 509–516.
17.
Cox, James D., N. Azarnia, Roger W. Byhardt, et al.. (1990). A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.. Journal of Clinical Oncology. 8(9). 1543–1555.
18.
Preisler, Harvey D., Azra Raza, Amy Early, et al.. (1987). Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.. Journal of Clinical Oncology. 5(5). 722–730.
19.
Gessner, Teresa, HD Preisler, N. Azarnia, et al.. (1987). Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy. Medical Oncology and Tumor Pharmacotherapy. 4(1). 23–31.
20.
Preisler, Harvey D. & N. Azarnia. (1984). Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay. British Journal of Haematology. 58(4). 633–640.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Dimitrios Colevas Breakdown of academic impact, for papers by Didier Cupissol Breakdown of academic impact, for papers by Jan B. Vermorken Breakdown of academic impact, for papers by Jan B. Vermorken Breakdown of academic impact, for papers by Frédéric Peyrade Breakdown of academic impact, for papers by F. Cognetti Breakdown of academic impact, for papers by Julie A. Kish Breakdown of academic impact, for papers by Ricardo Hitt Breakdown of academic impact, for papers by Federica Perrone Breakdown of academic impact, for papers by Muhyi Al‐Sarraf